101. Lung-targeted delivery of TGF-β antisense oligonucleotides to treat pulmonary fibrosis
- Author
-
Jung Hyun Kim, Sehoon Kim, Yun Sil Lee, Kyoung Ran Kim, Dae-Ro Ahn, Seulgi Jeon, Seong Jae Kang, Hien Bao Dieu Thai, and Seokyung Lee
- Subjects
Pulmonary Fibrosis ,medicine.medical_treatment ,Genetic enhancement ,Pharmaceutical Science ,02 engineering and technology ,Bleomycin ,Mice ,03 medical and health sciences ,Downregulation and upregulation ,Transforming Growth Factor beta ,In vivo ,Pulmonary fibrosis ,medicine ,Animals ,Lung ,030304 developmental biology ,0303 health sciences ,business.industry ,Respiratory disease ,Fibroblasts ,Oligonucleotides, Antisense ,021001 nanoscience & nanotechnology ,medicine.disease ,Blot ,medicine.anatomical_structure ,Cytokine ,Cancer research ,0210 nano-technology ,business - Abstract
Pulmonary fibrosis is a serious respiratory disease, with limited therapeutic options. Since TGF-β is a critical factor in the fibrotic process, downregulation of this cytokine has been considered a potential approach for disease treatment. Herein, we designed a new lung-targeted delivery technology based on the complexation of polymeric antisense oligonucleotides (pASO) and dimeric human β-defensin 23 (DhBD23). Antisense oligonucleotides targeting TGF-β mRNA were polymerized by rolling circle amplification and complexed with DhBD23. After complexation with DhBD23, pASO showed improved serum stability and enhanced uptake by fibroblasts in vitro and lung-specific accumulation upon intravenous injection in vivo. The pASO/DhBD23 complex delivered into the lung downregulated target mRNA, and subsequently alleviated lung fibrosis in mice, as demonstrated by western blotting, quantitative reverse-transcriptase PCR (qRT-PCR), immunohistochemistry, and immunofluorescence imaging. Moreover, as the complex was prepared only with highly biocompatible materials such as DNA and human-derived peptides, no systemic toxicity was observed in major organs. Therefore, the pASO/DhBD23 complex is a promising gene therapy platform with lung-targeting ability to treat various pulmonary diseases, including pulmonary fibrosis, with low side effects.
- Published
- 2020